Skip to main content

Advertisement

Table 2 Changes in C-peptide levels of the T1D subjects after treatment at 12 weeks.

From: Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells

Patient No. C-peptide (ng/ml) Changes in C-peptide levels (ng/ml)
Group A:   
1 0.56 ↑ 0.26
2 0.98 ↑ 0.42
3 0.54 ↑ 0.42
4 1.1 ↑ 0.46
5 0.52 ↑ 0.34
6 0.78 ↑ 0.60
Mean 0.75 ↑ 0.42
(SD) (0.24) (0.12)
Group B   
7 0.25 ↑ 0.24
8 0.11 ↑ 0.10
9 0.28 ↑ 0.27
10 0.43 ↑ 0.42
11 0.11 ↑ 0.10
12 0.12 ↑ 0.11
Mean 0.22 ↑ 0.21
(SD) (0.13) (0.13)
Control Group   
13 0.41 ↑ 0.04
14 0.38 ↓ 0.17
15 0.35 ↑ 0.05
Mean 0.38 ↓ 0.03
(SD) (0.03) (0.12)
  1. Levels of plasma C-peptide before treatment served as baseline for comparison. The level of C-peptide was increased (↑); the level of C-peptide was decreased (↓).